News Age-Related Macular Degeneration (AMD)

Brolucizumab (RTH258) for the treatment of wet age-related macular degeneration

New phase 3 trial data shows that brolucizumab (RTH258) 6 mg results in less instances of detected retinal fluid in treated patients versus those treated with aflibercept. The indication of treatment for the key marker of neovascular age-related macular degeneration (nAMD) lends to the hope that the humanized single-chain antibody fragment (scFv) can reach the market as a first-of-its-kind therapy.

Brolucizumab (RTH258) for the treatment of wet age-related macular degeneration

Bayer's eye drug Eylea approved in Europe

One of Eylea’s key selling points will be its less frequent dosing. Bayer’s drug is given every two months after three initial monthly injections, compared to monthly Lucentis injections.

Bayer's eye drug Eylea approved in Europe

FDA approves Eylea for eye disorder in older people

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

FDA approves Eylea for eye disorder in older people

International AMD Expert Summit convened in Berlin to improve treatment and outcomes for wet age-related macular degeneration

An international group of fifteen expert ophthalmologists have been convened in Berlin, Germany by the nonprofit Angiogenesis Foundation to share key perspectives and discuss strategies for improving the advocacy, treatment, and vision outcomes for 'wet' form of age-related macular degeneration (AMD), the most common form of blindness over the age of 50 in developed nations.

Is It Possible to Prevent the Inflammation that Triggers Dry Macular Degeneration? New Research Says Maybe

Most recently, researchers from the United States and Japan have discovered a "critical trigger" -an enzyme called cGAS, explained below- which starts the inflammation that damages cells and leads to dry AMD and geographic atrophy. Their hope is that this finding will halt inflammation early on in the course of the disease and prevent the progression to vision loss.

Is It Possible to Prevent the Inflammation that Triggers Dry Macular Degeneration?

International AMD Expert Summit convened in Berlin to improve treatment of Wet AMD

Can QLT catch the eye with trial retina drug?

Canadian eye drug developer QLT Inc. (QLT-T6.980.091.31%) has had its share of pain, with setbacks for a drug delivery system and slowing growth for Visudyne, its main drug, leaving investors to hope an experimental retinal diseases drug can get growth back on track.

Can QLT catch the eye with trial retina drug?

Positive Animal Studies for Novel Squalamine Eye Drop for Wet-AMD

Ohr Pharmaceutical today announced positive results from two critical animal studies on the recently announced Squalamine eye drop formulation for the treatment of wet-age related macular degeneration ("wet-AMD").

Positive Animal Studies for Novel Squalamine Eye Drop for Wet-AMD

The beam of energy that could save you from blindness

A hand-held device that fires sound waves into the eye could help prevent age-related macular degeneration (AMD), a leading cause of blindness.

The gadget uses the waves to help drugs get into the eye without the need for painful injections.

The beam of energy that could save you from blindness

Stem Cell Therapy for Age-Related Macular Degeneration - A Step Closer to Reality

The notion of transplanting adult stem cells to treat or even cure age-related macular degeneration has taken a significant step toward becoming a reality.

Stem Cell Therapy for Age-Related Macular Degeneration

Age Related Macular Degeneration: Top 5 Drugs That Work

Age related macular degeneration is a medical condition that results in distortion or loss of vision in the macula or center of the visual field in older adults due to damage to the retina. It is of two forms; "dry" and "wet".

Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs

Lpath will soon initiate two iSONEP Phase II trials: The PEDigree Study will evaluate the safety and efficacy of iSONEP in patients with RPE Detachment (PED), for which there is no approved drug, and the Nexus Study will evaluate the safety and efficacy in wet-AMD patients without PED. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

Lpath Granted Another Key U.S. Patent Related to iSONEP and ASONEP Drug Programs

Macular Degeneration: Will Discovery Bring Cure for Blindness?

There's still no cure for macular degeneration, an incurable eye disease that is the leading cause of blindness among older people. Is that about to change?

Macular Degeneration: Will Discovery Bring Cure for Blindness?

Current Research: Lutein, Zeaxanthin and Omega-3 Fatty Acids are Essential for Keeping Eyes Healthy

Nutritional Supplements are Recommended at an Older Age
current scientific review article has confirmed that an optimal supply of the carotenoids lutein and zeaxanthin, as well as the omega-3 fatty acids DHA and EPA, is essential for keeping our eyes healthy. The authors emphasise the potential of these nutrients for protection of the retinal cells and the prevention and treatment of age-related degenerative eye diseases, such as macular degeneration (AMD) in the elderly.

Lutein, Zeaxanthin and Omega-3 Fatty Acids are Essential for Keeping Eyes Healthy

Cataract Surgery may Benefit AMD Patients at All Stages

Cataract surgery improved vision in patients with any stage -from mild to advanced- AMD in the first study to include an adequate number of advanced AMD patients. Data was obtained from the multicenter, prospective Age-Related Eye Disease Study (AREDS)

Cataract Surgery may Benefit AMD Patients at All Stages

Omega-3 fatty acids appear to impact AMD progression

Omega-3 fatty acids found in fatty fish such as tuna and salmon may protect against progression of age-related macular degeneration (AMD), but the benefits appear to depend on the stage of disease and whether certain supplements are taken, report researchers at the Laboratory for Nutrition and Vision Research (LNVR), Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University.

Omega-3 fatty acids appear to impact AMD progression

Cataract Surgery Doesn't Worsen AMD

Cataract surgery doesn't hasten vision loss in people with age-related macular degeneration (AMD).

That's the conclusion of a new study that challenges the findings of several large epidemiological studies that suggested a link between cataract surgery and accelerated AMD progression.

Cataract Surgery Doesn't Worsen AMD

Macular Degeneration - A Closer Look

Macular degeneration is a deterioration or breakdown of the macula. The macula is a small area in the retina at the back of the eye that allows you to see fine details clearly and perform activities such as reading and driving. When the macula does not function correctly, your central vision can be affected by blurriness, dark areas or distortion. Macular degeneration affects your ability to see near and far, and can make some activities - like threading a needle or reading - difficult or impossible.

Macular Degeneration - A Closer Look

Age-Related Macular Degeneration (AMD) - Therapy / Treatment

The second group of reports includes Internal Radiation for AMD and an overview of a wide range of upcoming therapies, as well as an update on artificial vision.

CCR3 - New therapeutic approach in the early stages of wet macular degeneration

Early detection and treatment of wet macular degeneration will be facilitated

myVisionTrack App in Development To Test Vision Changes in People With Macular Degeneration

An upcoming iPhone/iPod Touch app called myVisionTrack will give macular degeneration and diabetic retinopathy patients the ability to monitor changes in their vision over time. This in turn can help their eye doctor adjust treatment as needed.

myVisionTrack To Test Vision Changes in People With Macular Degeneration

Drug Shows Promise Against Vision Loss

The drug, called Macugen, is intended to treat the wet form of age-related macular degeneration, a disease that can rob people of the ability to read, drive, recognize faces or watch television. More than 200,000 cases of wet macular degeneration are diagnosed each year in the United States.

Drug Shows Promise Against Vision Loss

Presse Altersbedingte Makuladegeneration